Harry Enten is a senior political writer and analyst for FiveThirtyEight, a polling aggregation website and blog.
Harry Enten on KCRW
More from KCRW
The enviable life of a true American publisher
PoliticsFewer people in the world had access to the personal moments experienced by Steve Wasserman, Heyday Books publisher, former LA Times Book Review editor and former editor at several of…
Can Americans trust justice and national security amid Trump transition?
PoliticsWill Donald Trump reduce U.S. interventionism? Did President Biden open a can of worms by pardoning his son Hunter? Plus, KCRW looks at what justice means post-election.
Overlooked voters could sway close OC race, thanks to nonprofit
Election 2024Young progressives with Chispa rallied Latino voters for Democrat Derek Tran in OC’s 45th District, a race that hasn’t been called.
Pushback brews following ‘Morning Joe’ visit to Mar-A-Lago
PoliticsWhat should the media consider when covering Trump’s second term? Plus, Surgeon General Dr. Vivek Murthy discusses the loneliness epidemic.
Was civility the winner of the VP debate?
PoliticsCan civility influence voters in the Trump era? Has Biden’s policy in the Middle East backfired? Plus, the United States hits a bleak milestone on executions.
Trump and Harris try distancing themselves from campaign mistakes
PoliticsKCRW provides an election outlook with a week to go. Can the electorate stop being driven by hate? Plus, what was the Washington Post’s real mistake?
Got parking in Inglewood? Congrats, you’re winning
TransportationWith the new stadiums in Inglewood, businesses with parking are thriving, while those without feel the city’s economic boom is passing them by.
Will Trump or Harris win undecided voters?
Election 2024The final campaign days are here. How are early voters affecting candidate strategies? Plus, the panel discusses how abortion rights may change the Nevada battleground.
Irvine police buys $150K Cybertruck, critics call it unnecessary
LawThe Irvine Police Department purchased a Tesla Cybertruck to promote its D.A.R.E drug program. But some taxpayers say the money should be spent elsewhere.